KZA kazia therapeutics limited

Ann: GDC 0084 progress update, page-4

  1. 24,988 Posts.
    lightbulb Created with Sketch. 985
    Hopefully soon they will announce the financial details of the MSA

    Novogen has signed a Master Services Agreement (MSA) with Chiltern Oncology in relation to conduct of the phase II clinical trial of GDC-0084.

    Chiltern Oncology is a leading international contract research organization, with a specialist capability in trials of novel anti-cancer agents.

    The MSA details key terms of the proposed working relationship, but implementation of the study will be subject to further contractual negotiations.
    Last edited by Merchant2000: 22/08/17
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.